Nektar Therapeutics buy TD Cowen
Start price
09.11.23
/
50%
€0.47
Target price
09.11.24
-
Performance (%)
216.45%
End price
10.11.24
€1.50
Summary
This prediction ended on 10.11.24 with a price of €1.50. With a performance of 216.45% the BUY prediction by TD_Cowen was a big success. TD_Cowen has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by TD_Cowen for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von TD_Cowen gewählte maximale Laufzeit wurde überschritten